EMBL Australia

EMBL Australia group leader Dr William Roman & his team have launched a new imaging-based spatial transcriptomics platform that dramatically reduces experimental costs from more than $35,000 to approximately $30 per experiment, making spatial biology more accessible to researchers across Australia.

EMBL Australia Group Leader Dr Senthil Arumugam has co-launched the Monash BDI Advanced Bioimaging (MAB) platform – a researcher-led, global collaboration hub designed to bring innovative microscopy technologies directly to the researchers who need them.

In addition to translating discoveries to improve patients’ lives, our group leaders develop transformative tools for the scientific community. One such innovation is a freely available, ultracompact and highly sensitive 3D-printed microscope with the potential to revolutionise health diagnostics.

EMBL Australia group leaders are deeply integrated into Australian and international networks of excellence. They have established themselves as scientists and drive research and innovation in areas of national scientific priority.

In an era of transforming technologies in molecular sequencing, imaging, and artificial intelligence, there is an urgent need for skilled researchers who can bridge the gap between biomedical and computational sciences. Professor Eduardo Eyras is helping address that gap.

Dr Vaishnavi Ananthanarayanan is an innovative cell biologist whose research explores the intricate mechanisms of cellular organisation and a passionate advocate for equity, diversity and inclusion (EDI) in science.

A/Prof Maté Biro (UNSW Sydney) combines his expertise in cellular biology and advanced microscopy to improve cancer treatment efficacy, paving the way for next-generation therapies that could revolutionise the fight against cancer.

A/Prof Mikaël Martino (Monash University) is a renowned innovator in regenerative medicine, known for translating ground-breaking technologies into impactful solutions with the potential to reshape tissue repair and improve patient outcomes.

The long-term support and stability provided to EMBL Australia group leaders enables them to drive transformative advances in Australian research infrastructure, just as Professor David Lynn did.